Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-101

The wider market is having a wobble, first to get cut from most portfolios are non earning companies. BOT had a lot of meat cut from the bone with the CR ,, that didn't leave much insulation around the SP, the circa 26% decline from the CR strike price of 11c is in line with a wider small caps decline.
An easy play is buy what you can down here and you can still take a 25% gain before the Insto reaches for the sale button..
Many have mentioned the Biotech Cycle, I know some investors who call it the Bio Bank,, a decade before payback, BOT told a great story, initial clinical trials have demonstrated there warrants further investigation, is there a potential market for the products,, "You Bet there is" are there Players who currently revenue Billions from the only 2 patented base products approved by the FDA, "you Bet" Both of which do not contain any natural products.
The market want to know BOT have a clear exit strategy, who and when plus how much $$ needs to be highlighted.
BOT also need to define completion dates , time frame for analysis of Data. If there was a more definitive date the Company could begin to highlight the commercial opportunity for investment..
Dilution has dampened investor interest also the company now has 750,000,000 shares ..with 139,000,000 still to be rinsed by our Insto.... with fantastic news and a 50% increase in SP our insto will then begin the sell off,, they have been locked in now for 4 months with no chance of a return... Their investors will be getting twitchy,,,,
Remember not often do we get to buy at such a discount to an Insto....